A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
The purpose of this study is to confirm the safety and tolerability of oral panobinostat (PAN) in combination with a fixed dose of 5-Azacitidine (5-Aza) in adult Japanese patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML).
Myelodysplastic Syndromes (MDS)|Chronic Myelomonocytic Leukemia (CMML)|Acute Myeloid Leukemia (AML)
DRUG: Panobinostat
Incidence of Dose Limiting Toxicitiy(DLT), DLT will be assessed during PK run-in period (up to 7 days) and 1st cycle (28 days), first 5 weeks of treatment period
PK parameter - Cmax, Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours|PK parameter - Tmax, Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours|PK parameter - AUC (AUC0-48, AUC0-tlast), Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours|PK parameter - T1/2 (apparent oral clearance, volume distribution), Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours|PK parameter - AUC0-inf, Day 1 to 3 of PK run-in period; pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours|Trough level of PAN in combination with 5-Aza, Day 4, 5, 8 of the 1st cycle; pre-dose (0 hour)|Frequency and severity of Adverse Events (AEs), Safety will be measured in terms of type, frequency and severity of adverse events according to CTCAE v4.03., Participants will be followed for the duration of treatment, an expected average of 6 months|Laboratory abnormalities, duration of treatment, an expected average of 6 months
The purpose of this study is to confirm the safety and tolerability of oral panobinostat (PAN) in combination with a fixed dose of 5-Azacitidine (5-Aza) in adult Japanese patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML).